Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
The gay hockey show no one saw coming — and everyone is suddenly obsessed with - 2Euclid space telescope sees gorgeous cosmic cloud | Space photo of the day for Nov. 18, 2025
- 3Earth’s magnetic field protects life on Earth from radiation, but it can move, and the magnetic poles can even flip
- 4Family-Accommodating Snow Sports Experiences
- 5This cafe takes orders in sign language. It's cherished by the Deaf community
- West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology
- From invasive species tracking to water security – what’s lost with federal funding cuts at US Climate Adaptation Science Centers
- Report in relation to renaming Herzog Park set to be withdrawn
- Cells have more mini ‘organs’ than researchers thought − unbound by membranes, these rogue organelles challenge biology’s fundamentals
- Manual for 10 Scrumptious Specialty Mixed drinks
- Find the Abilities Required for Advanced Advertising Position
- Etymological Investigation Disclosed: A Survey of \Dominating New Tongues\ Language Learning Application
- Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
- Study reveals links between global food systems, obesity, and climate change
